Henry Schein, Inc. (HSIC)
NASDAQ: HSIC · Real-Time Price · USD
69.82
+0.87 (1.26%)
Dec 20, 2024, 4:00 PM EST - Market closed
Henry Schein Revenue
Henry Schein had revenue of $3.17B in the quarter ending September 28, 2024, with 0.38% growth. This brings the company's revenue in the last twelve months to $12.50B, down -1.53% year-over-year. In the year 2023, Henry Schein had annual revenue of $12.34B, down -2.44%.
Revenue (ttm)
$12.50B
Revenue Growth
-1.53%
P/S Ratio
0.72
Revenue / Employee
$499,960
Employees
25,000
Market Cap
8.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 12.34B | -308.00M | -2.44% |
Dec 31, 2022 | 12.65B | 246.00M | 1.98% |
Dec 25, 2021 | 12.40B | 2.28B | 22.55% |
Dec 26, 2020 | 10.12B | 133.20M | 1.33% |
Dec 28, 2019 | 9.99B | 568.20M | 6.03% |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 26, 2015 | Pro | Pro | Pro |
Dec 27, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Charles River Laboratories International | 4.06B |
Bruker | 3.24B |
Bio-Rad Laboratories | 2.58B |
Bio-Rad Laboratories | 2.58B |
Masimo | 2.04B |
HealthEquity | 1.15B |
Repligen | 633.51M |
Intra-Cellular Therapies | 613.73M |
HSIC News
- 4 days ago - Henry Schein to Participate at J.P. Morgan's Healthcare Investor Conference - Business Wire
- 4 weeks ago - Activist Ananym has a list of suggestions for Henry Schein. How the firm can help improve profits - CNBC
- 4 weeks ago - Henry Schein to Participate in Investor Conferences in December - Business Wire
- 4 weeks ago - Henry Schein to Acquire Acentus, a Leading Supplier of Homecare Medical Products - Business Wire
- 4 weeks ago - Exclusive: Activist investor Ananym Capital pushes for changes at Henry Schein, sources say - Reuters
- 4 weeks ago - Dental supply stock rallies on theory RFK's anti-fluoride stance will prompt more dentist visits - CNBC
- 6 weeks ago - Henry Schein, Inc. (HSIC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Henry Schein beats quarterly profit estimates on lower costs - Reuters